Alto Neuroscience (ANRO) Competitors $3.80 -0.08 (-1.93%) Closing price 09/25/2025 03:58 PM EasternExtended Trading$3.80 -0.01 (-0.13%) As of 09/25/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. UPXI, IMRX, ADCT, AURA, DRUG, CGEM, TVRD, AUTL, LBRX, and BNTCShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Upexi (UPXI), Immuneering (IMRX), ADC Therapeutics (ADCT), Aura Biosciences (AURA), Bright Minds Biosciences (DRUG), Cullinan Therapeutics (CGEM), Tvardi Therapeutics (TVRD), Autolus Therapeutics (AUTL), LB Pharmaceuticals (LBRX), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors Upexi Immuneering ADC Therapeutics Aura Biosciences Bright Minds Biosciences Cullinan Therapeutics Tvardi Therapeutics Autolus Therapeutics LB Pharmaceuticals Benitec Biopharma Upexi (NASDAQ:UPXI) and Alto Neuroscience (NYSE:ANRO) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the media refer more to UPXI or ANRO? In the previous week, Upexi had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Upexi and 4 mentions for Alto Neuroscience. Upexi's average media sentiment score of 1.30 beat Alto Neuroscience's score of 0.29 indicating that Upexi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, UPXI or ANRO? Upexi has a beta of -0.47, indicating that its share price is 147% less volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Is UPXI or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Alto Neuroscience's return on equity of -44.34% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Upexi-135.86% -535.19% -122.94% Alto Neuroscience N/A -44.34%-36.73% Which has higher valuation & earnings, UPXI or ANRO? Upexi has higher revenue and earnings than Alto Neuroscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$26M11.96-$23.66MN/AN/AAlto NeuroscienceN/AN/A-$61.43M-$2.39-1.59 Do institutionals and insiders have more ownership in UPXI or ANRO? 5.7% of Upexi shares are held by institutional investors. 4.4% of Upexi shares are held by insiders. Comparatively, 11.1% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer UPXI or ANRO? Upexi presently has a consensus target price of $15.50, indicating a potential upside of 193.56%. Alto Neuroscience has a consensus target price of $8.50, indicating a potential upside of 123.39%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upexi is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryUpexi beats Alto Neuroscience on 8 of the 14 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$105.06M$3.13B$5.74B$21.61BDividend YieldN/A2.39%5.75%3.52%P/E Ratio-1.5920.6375.9529.18Price / SalesN/A442.69546.8359.53Price / CashN/A44.6737.5424.32Price / Book0.689.6212.664.52Net Income-$61.43M-$52.73M$3.29B$1.00B7 Day Performance4.82%1.81%0.25%-0.84%1 Month Performance-7.98%5.50%2.80%1.80%1 Year Performance-68.29%18.12%63.42%12.54% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience2.2022 of 5 stars$3.81-1.9%$8.50+123.4%-67.5%$105.06MN/A-1.59N/AUPXIUpexi3.4702 of 5 stars$6.07-7.8%$15.50+155.4%+19.0%$387.49M$26M0.00130Positive NewsUpcoming EarningsGap DownIMRXImmuneering3.5052 of 5 stars$8.73-5.7%$13.75+57.5%+172.1%$384.94M$320K-4.6260News CoverageAnalyst ForecastGap UpADCTADC Therapeutics2.0721 of 5 stars$3.46+1.0%$7.75+124.3%+12.4%$384.75M$70.84M-2.20310AURAAura Biosciences1.9878 of 5 stars$6.16+1.3%$22.00+257.1%-32.0%$377.69MN/A-3.1450Positive NewsDRUGBright Minds Biosciences3.2289 of 5 stars$51.11-4.1%$81.00+58.5%+4,121.8%$375.30MN/A-54.96N/APositive NewsCGEMCullinan Therapeutics2.295 of 5 stars$6.28+1.3%$26.00+314.0%-63.3%$366.26MN/A-1.9430Positive NewsTVRDTvardi Therapeutics2.47 of 5 stars$37.40-2.2%$64.25+71.8%N/A$358.59M$7.14M0.0080News CoverageAUTLAutolus Therapeutics3.9965 of 5 stars$1.38+3.0%$9.12+560.9%-56.5%$356.63M$10.12M-1.64330Positive NewsAnalyst ForecastLBRXLB PharmaceuticalsN/A$16.02+0.9%N/AN/A$356.39MN/A0.0016News CoverageBNTCBenitec Biopharma1.7087 of 5 stars$13.51+0.4%$24.80+83.6%+56.8%$353.07M$80K-8.9520Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Upexi Competitors Immuneering Competitors ADC Therapeutics Competitors Aura Biosciences Competitors Bright Minds Biosciences Competitors Cullinan Therapeutics Competitors Tvardi Therapeutics Competitors Autolus Therapeutics Competitors LB Pharmaceuticals Competitors Benitec Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANRO Stock Alerts